4DMedical Statistics
Total Valuation
4DMedical has a market cap or net worth of 1.56 billion. The enterprise value is 1.56 billion.
| Market Cap | 1.56B |
| Enterprise Value | 1.56B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 569.79M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.52% |
| Shares Change (QoQ) | -62.76% |
| Owned by Insiders (%) | 3.85% |
| Owned by Institutions (%) | 1.12% |
| Float | 468.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 406.89 |
| PB Ratio | 37.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -79.11 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -68.83 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.07.
| Current Ratio | 0.89 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | -186.22 |
Financial Efficiency
Return on equity (ROE) is -44.49% and return on invested capital (ROIC) is -41.06%.
| Return on Equity (ROE) | -44.49% |
| Return on Assets (ROA) | -27.64% |
| Return on Invested Capital (ROIC) | -41.06% |
| Return on Capital Employed (ROCE) | -62.87% |
| Weighted Average Cost of Capital (WACC) | 19.50% |
| Revenue Per Employee | 30,948 |
| Profits Per Employee | -158,984 |
| Employee Count | 124 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.49 |
Taxes
| Income Tax | -57,115 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +544.12% in the last 52 weeks. The beta is 2.78, so 4DMedical's price volatility has been higher than the market average.
| Beta (5Y) | 2.78 |
| 52-Week Price Change | +544.12% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.38 |
| Average Volume (20 Days) | 30,704 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4DMedical had revenue of 3.84 million and -19.71 million in losses. Loss per share was -0.09.
| Revenue | 3.84M |
| Gross Profit | 3.53M |
| Operating Income | -31.14M |
| Pretax Income | -19.77M |
| Net Income | -19.71M |
| EBITDA | -30.19M |
| EBIT | -31.14M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 4.51 million in cash and 2.82 million in debt, with a net cash position of 1.69 million.
| Cash & Cash Equivalents | 4.51M |
| Total Debt | 2.82M |
| Net Cash | 1.69M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 42.11M |
| Book Value Per Share | 0.09 |
| Working Capital | -1.44M |
Cash Flow
In the last 12 months, operating cash flow was -22.60 million and capital expenditures -56,276, giving a free cash flow of -22.66 million.
| Operating Cash Flow | -22.60M |
| Capital Expenditures | -56,276 |
| Free Cash Flow | -22.66M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 92.07% |
| Operating Margin | -811.49% |
| Pretax Margin | -515.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4DMedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.52% |
| Shareholder Yield | -14.52% |
| Earnings Yield | -1.26% |
| FCF Yield | -1.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4DMedical has an Altman Z-Score of -0.74 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.74 |
| Piotroski F-Score | 1 |